Shares of Procter & Gamble Hygiene and Health Care Limited came under focus after management outlined its growth plans during a virtual interaction with analysts and investors, as the company seeks to revive revenue growth after three years of largely flat sales.
With a market capitalisation of about Rs. 29,241.44 crore, the stock was trading at Rs. 9,008.25, close to its 52-week low of Rs. 8,883.50. The shares have fallen more than 30 percent over the past year. The stock trades at a P/E of around 34.14.
Growth outlook remains unchanged
Management said its Integrated Growth Strategy remains intact despite recent leadership changes. The approach is built around:
- Focused portfolio
- Product superiority
- Cost productivity
- Constructive disruption
- Organisational engagement
The company expects:
- Feminine hygiene category growth: 7-10 percent
- Healthcare category growth: 2-3 percent
Healthcare demand remains sensitive to monsoon patterns because of its dependence on the cough-and-cold season.
Over the long term, management expects both categories to grow at a mid-to-high single-digit rate and aims to drive category expansion through innovation.
Competition has intensified
Investors questioned why revenue has remained largely unchanged despite continued spending on advertising, wider distribution and regular product launches.
Management attributed the slowdown to:
- Changing consumer preferences.
- Increasing competitive intensity.
According to the company, more than 50 regional and direct-to-consumer brands have entered the feminine hygiene segment over the past decade.
Rather than chasing broad-based volume growth, the company said it is focusing on specific segments such as:
- Night-time period care.
- Period panties.
Period panties emerge as a key growth area
Management highlighted strong growth in the period panties segment.
Key highlights include:
- More than 10 crore units sold during FY26.
- The category tripled in size during the year.
- One in four quick-commerce customers buying period products now opt for period panties instead of traditional sanitary pads.
- The company’s brand holds the leading position across quick-commerce platforms.
Healthcare portfolio sees product upgrades
In healthcare, management said a two-year overhaul of its cough drops portfolio helped deliver double-digit offtake growth and market share gains.
Changes included:
- Higher active ingredient content.
- Introduction of a larger lozenge format.
The company also launched:
- A reformulated melatonin-and-ashwagandha sleep gummy.
- A new cough syrup.
Management said steady product improvements, rather than infrequent large launches, remain its preferred strategy.
Cost savings support margins
The company generated Rs. 86 crore in savings through productivity initiatives during the year.
As a result:
- Structural operating margins improved by one percentage point.
- Savings are being reinvested into brands, advertising and distribution.
Management said the “save-to-reinvest” approach will continue to support premiumisation and future investments.
Input costs remain a concern
The company said crude oil and resin prices have risen by 30-50 percent amid the West Asia conflict.
Despite the increase, management said:
- No stockouts have occurred.
- Product quality has been maintained.
- Supplier partnerships and continuity planning have helped manage disruptions.
However, it cautioned that volatility in costs and availability could continue into FY27.
FY26 performance
For the year ended March 2026, the company reported:
| Particulars | FY26 |
|---|---|
| Sales | ~Rs. 4,300 crore |
| Profit after tax | ~Rs. 850 crore |
| PAT growth | 19% |
Revenue remained broadly unchanged from the previous year, while profits benefited from productivity measures.
About the company
Procter & Gamble Hygiene and Health Care Limited, incorporated in 1964 as Richardson Hindustan Limited and acquired by Procter & Gamble in 1985, operates in the feminine hygiene and healthcare segments.
Its flagship brands include:
- Whisper in feminine hygiene.
- Vicks in healthcare.
TL;DR
P&G Hygiene said premium products, category innovation and productivity savings will drive future growth after three years of flat sales. The company generated Rs. 86 crore in savings in FY26, while period panties and healthcare product upgrades emerged as important growth drivers.
AI summary
- P&G Hygiene expects 7-10% growth in feminine hygiene and 2-3% in healthcare.
- Period panties sold over 10 crore units during FY26.
- The company generated Rs. 86 crore in productivity savings.
- Crude and resin prices have risen 30-50% due to the West Asia conflict.
- FY26 sales were broadly flat at Rs. 4,300 crore, while PAT rose 19% to Rs. 850 crore.





